{"product_id":"combining-lifestyle-changes-with-medications-or-supplements-to-prevent-alzheimers-disease-what-the-research-shows","title":"Combining Lifestyle Changes with Medications or Supplements to Prevent Alzheimer's Disease: What the Research Shows","description":"\u003cp\u003eThis systematic review examined 12 randomized controlled trials that combined multidomain lifestyle interventions with drugs, supplements, or medical foods to prevent or slow Alzheimer's disease and related dementias. The trials enrolled a total of 4,434 participants, with intervention periods ranging from 6 to 36 months. Physical exercise was the most common lifestyle component, appearing in all 12 trials. While no single trial showed a definitive benefit on its primary cognitive outcome, several trials found positive results in specific subgroups, particularly in people at higher risk of dementia. The authors conclude that well-designed combination interventions, tailored to the right individuals and implemented at the optimal time, may effectively improve cognition, but trial methods need further refinement.\u003c\/p\u003e\n\n\u003ch1\u003eCombining Lifestyle Changes with Medications or Supplements to Prevent Alzheimer's Disease: What the Research Shows\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n\u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#characteristics\"\u003eCharacteristics of the Combination Trials\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#duration\"\u003eDuration, Frequency, and Types of Intervention\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#outcomes\"\u003eHow Outcomes Were Measured\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#omega3\"\u003eLifestyle Interventions Combined with Omega-3 Fatty Acids\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#bbh\"\u003eLifestyle Intervention Combined with BBH-1001\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#other\"\u003eOther Combination Approaches\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#implications\"\u003eWhat These Findings Mean for Patients\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of the Research\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations and Next Steps\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eA review of 12 randomized trials with 4,434 participants found no single trial showed a definitive benefit on its primary cognitive outcome.\u003c\/li\u003e\n\u003cli\u003eSome trials found positive results in specific subgroups, particularly people at higher risk of dementia, such as those with higher risk scores or amyloid plaques.\u003c\/li\u003e\n\u003cli\u003ePhysical exercise appeared in all 12 trials; cognitive training and dietary guidance were also common components.\u003c\/li\u003e\n\u003cli\u003eOmega-3 supplementation had an excellent safety profile, but cognitive benefits were not consistently demonstrated across trials.\u003c\/li\u003e\n\u003cli\u003eResearchers recommend early, personalized interventions and refined trial methods, as no combination has yet proven definitively effective.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eAlzheimer's disease (AD) and related dementias (ADRD) remain among the most pressing health challenges worldwide. Effective treatments are still not widely available. Researchers are working urgently to find new compounds, as well as to repurpose existing drugs, that might delay the onset of dementia, slow its progression, or ultimately prevent it altogether.\u003c\/p\u003e\n\n\u003cp\u003eRecent progress with anti-amyloid beta monoclonal antibody therapies, including Lecanemab and Donanemab, has shown potential in slowing cognitive decline. However, current estimates indicate that fewer than 30% of Alzheimer's patients would be eligible for these therapies. This limited eligibility highlights the need for broader approaches.\u003c\/p\u003e\n\n\u003cp\u003eMany single-target treatments, whether pharmacological (drug-based) or non-pharmacological, have failed in Alzheimer's disease trials. This failure underscores a fundamental limitation: targeting only one disease mechanism or one risk factor is not enough. The complexity of dementia demands strategies that address multiple risk factors and biological pathways at the same time.\u003c\/p\u003e\n\n\u003cp\u003eTiming matters greatly. Early intervention in the Alzheimer's disease continuum appears crucial for achieving the best preventive effect. New multidomain therapeutic approaches could enhance treatment efficacy and allow prevention efforts to be personalized to each individual.\u003c\/p\u003e\n\n\u003cp\u003eThe Lancet Commission on Dementia Prevention, Intervention and Care recently updated its list of modifiable risk factors for dementia. The commission identified 14 factors, mostly based on observational studies:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eLow education\u003c\/li\u003e\n\u003cli\u003eHearing and vision loss\u003c\/li\u003e\n\u003cli\u003eTraumatic brain injury\u003c\/li\u003e\n\u003cli\u003eHypertension (high blood pressure)\u003c\/li\u003e\n\u003cli\u003eExcessive alcohol use\u003c\/li\u003e\n\u003cli\u003eObesity\u003c\/li\u003e\n\u003cli\u003eSmoking\u003c\/li\u003e\n\u003cli\u003eDepression\u003c\/li\u003e\n\u003cli\u003eSocial isolation\u003c\/li\u003e\n\u003cli\u003ePhysical inactivity\u003c\/li\u003e\n\u003cli\u003eAir pollution\u003c\/li\u003e\n\u003cli\u003eDiabetes\u003c\/li\u003e\n\u003cli\u003eHigh levels of low-density lipoprotein (LDL) cholesterol\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eModifying these factors could prevent or delay up to 45% of dementia cases. This is a substantial proportion, and it means that lifestyle and risk factor management have enormous potential for reducing the global burden of dementia.\u003c\/p\u003e\n\n\u003cp\u003eThe World Health Organization (WHO) guidelines for risk reduction of cognitive decline and dementia are based on a synthesis of findings from intervention trials. These guidelines recommend physical activity, a healthy balanced diet, cognitive training, and management of hypertension, diabetes, and dyslipidemia (abnormal cholesterol levels) for reducing the risk of cognitive decline. The WHO guidelines are currently being updated, and the new edition will include additional modifiable lifestyle factors and multidomain interventions.\u003c\/p\u003e\n\n\u003cp\u003eMultidomain lifestyle interventions, such as the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER), have reported promising cognitive benefits in older individuals at risk of dementia. This includes people with genetic susceptibility, specifically carriers of the APOE-ε4 allele (a genetic variant that increases Alzheimer's risk). The FINGER randomized controlled trial combined five components over a 2-year intervention period:\u003c\/p\u003e\n\n\u003col\u003e\n\u003cli\u003eExercise\u003c\/li\u003e\n\u003cli\u003eCognitive training\u003c\/li\u003e\n\u003cli\u003eSocial engagement\u003c\/li\u003e\n\u003cli\u003eDietary recommendations\u003c\/li\u003e\n\u003cli\u003eVascular and metabolic risk factor management\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe FINGER study is now a model for similar trials around the world. The World-Wide FINGERS (WW-FINGERS) network includes 70 member countries and offers a new paradigm to prevent cognitive decline.\u003c\/p\u003e\n\n\u003cp\u003eGiven the growing number of modifiable risk factors being identified for late-life dementia, there is an increasing need for novel multidomain combination trials. Integrating multidomain lifestyle interventions with pharmacological treatments, whether new or repurposed, holds promise for advancing precision medicine approaches. These approaches aim to prevent cognitive decline and dementia by tailoring interventions to individual needs. Existing strategies for cardiovascular and cancer treatment offer useful models for testing combination therapies in Alzheimer's disease and related dementias trials.\u003c\/p\u003e\n\n\u003cp\u003eOver the past decade, combination trials in the Alzheimer's disease field have been initiated. These trials focus on combinations of multidomain non-pharmacological lifestyle interventions and pharmacological compounds. In this context, the authors conducted a systematic review to provide a comprehensive overview of such combination randomized controlled trials.\u003c\/p\u003e\n\n\u003cp\u003eThe review focused on key methodological aspects, including intervention and trial design, target populations, intervention duration, and adherence. The aim was to inform the design of future combination trials. This would be done by identifying common pitfalls. It would also explore how current and emerging trial evidence can be leveraged to optimize trial design. This can guide the development of more effective intervention strategies.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Research Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. This is a widely accepted standard for conducting and reporting systematic reviews.\u003c\/p\u003e\n\n\u003cp\u003eTo identify combination therapy randomized controlled trials, the researchers searched records in Clinicaltrials.gov and euclinicaltrials.eu databases. They used the following search terms: \"Alzheimer's disease,\" \"mild cognitive impairment,\" \"dementia,\" and \"cognitive decline,\" combined with either \"lifestyle intervention,\" \"multidomain,\" or \"multimodal.\" The search covered records from inception to May 30, 2025. PubMed and EMBASE were also searched with the same combination of terms to catch any studies that might have been missed. All searches were performed independently by two researchers.\u003c\/p\u003e\n\n\u003cp\u003eThe review used the Population\/Intervention\/Comparator\/Outcomes (PICO) framework to define what studies to include. The review aimed to identify randomized controlled trials targeting adults with:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eNormal cognition\u003c\/li\u003e\n\u003cli\u003eSubjective cognitive decline (SCD), which is when a person notices memory or thinking problems but tests show normal function\u003c\/li\u003e\n\u003cli\u003eMild cognitive impairment (MCI), which is a noticeable decline in thinking skills that is greater than expected for age but does not interfere significantly with daily life\u003c\/li\u003e\n\u003cli\u003eProdromal Alzheimer's disease, which is the stage just before full dementia develops\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe studies had to test lifestyle-based interventions that addressed at least 2 modifiable risk factors for dementia, or included at least 2 intervention components. These lifestyle interventions had to be combined with additional treatments, such as:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003ePharmacological treatments (drugs)\u003c\/li\u003e\n\u003cli\u003eNutraceutical treatments (medical food or dietary supplements)\u003c\/li\u003e\n\u003cli\u003eNon-invasive devices (such as transcranial brain stimulation)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe studies also had to include appropriate comparators, such as placebo, standard care, or a lower-intensity intervention. They had to assess the intervention's effect on outcomes related to dementia and cognitive impairment.\u003c\/p\u003e\n\n\u003cp\u003eRandomized controlled trials were included regardless of their current status (ongoing, completed, terminated, or unknown) or whether published results were available. The researchers excluded trials with interventions or treatments that lasted less than 6 months.\u003c\/p\u003e\n\n\u003cp\u003eStudies were also excluded if they included participants with a suspected or known dementia diagnosis, or other major neurological or psychiatric disorders. Examples of excluded conditions included Parkinson's disease, stroke, major depression, multiple sclerosis, schizophrenia, and bipolar disorder. Studies were also excluded if participants had a history of substance abuse. Studies were also excluded if they focused on rehabilitation programs for recent cardiovascular, cerebrovascular, respiratory, or other medical events. An example of such a program is post-surgery rehabilitation.\u003c\/p\u003e\n\n\u003cp\u003eThe search was not limited by date of publication or geographical location. However, only records or publications in English were included.\u003c\/p\u003e\n\n\u003cp\u003eThe Covidence systematic review software was used to manage search results from Clinicaltrials.gov, PubMed, and EMBASE. Records derived from euclinicaltrials.eu were manually checked. After duplicates were removed, titles and abstracts were screened independently by two researchers. The full texts of potentially eligible studies were then obtained and further assessed. Any disagreement on inclusion was resolved by consensus within the research team.\u003c\/p\u003e\n\n\u003cp\u003eFor eligible randomized controlled trials, the researchers extracted a comprehensive set of data. This included:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eNational Clinical Trial (NCT) number\u003c\/li\u003e\n\u003cli\u003eStudy title and acronym\u003c\/li\u003e\n\u003cli\u003eCurrent status\u003c\/li\u003e\n\u003cli\u003eNumber of trial arms\u003c\/li\u003e\n\u003cli\u003eDrug component and dose\u003c\/li\u003e\n\u003cli\u003eLifestyle intervention domains\u003c\/li\u003e\n\u003cli\u003eIntervention intensity or modality\u003c\/li\u003e\n\u003cli\u003ePrimary and secondary outcomes\u003c\/li\u003e\n\u003cli\u003eTrial duration\u003c\/li\u003e\n\u003cli\u003eAge for study inclusion\u003c\/li\u003e\n\u003cli\u003eStudy population within the Alzheimer's disease continuum\u003c\/li\u003e\n\u003cli\u003eTrial sample size and timeframe\u003c\/li\u003e\n\u003cli\u003eMasking (blinding) approach\u003c\/li\u003e\n\u003cli\u003eTrial phase\u003c\/li\u003e\n\u003cli\u003eSponsor\u003c\/li\u003e\n\u003cli\u003eNumber of sites and countries\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"characteristics\"\u003eCharacteristics of the Combination Trials\u003c\/h2\u003e\n\n\u003cp\u003eThe search strategy initially identified 1,352 randomized controlled trials and 7,087 publications. After removing duplicates, 2,039 publications were screened to assess combinations of lifestyle interventions with pharmacological, nutraceutical, or other treatments. This screening process resulted in the identification of 12 combination randomized controlled trials as of May 30, 2025.\u003c\/p\u003e\n\n\u003cp\u003eThese 12 trials used several classes of compounds combined with multidomain lifestyle interventions. The trials targeted individuals within the continuum of Alzheimer's disease and dementia risk. This included people with normal cognition but increased dementia risk due to risk factors that were not well controlled, identified via validated scores. It also included people with a diagnosis of subjective cognitive decline (SCD) or mild cognitive impairment (MCI), defined via different sets of diagnostic criteria, or prodromal Alzheimer's disease.\u003c\/p\u003e\n\n\u003cp\u003eTwo randomized controlled trials included both MCI and early-stage dementia. For some trials, participants' inclusion relied on cognitive screening and assessment of modifiable risk factors. Examples include the MET-FINGER trial and the Multidomain Alzheimer Preventive Trial (MAPT).\u003c\/p\u003e\n\n\u003cp\u003eOne trial specifically included participants with MCI who also had concomitant type 2 diabetes (T2D) or insulin resistance. Two studies adopted a precision medicine approach by enriching their study populations with individuals carrying the APOE-ε4 allele. This means they specifically recruited people with this genetic risk factor.\u003c\/p\u003e\n\n\u003cp\u003eSeven randomized controlled trials targeted participants with prodromal Alzheimer's disease, mild cognitive impairment, or early dementia. Five trials focused on at-risk individuals or people with subjective cognitive decline.\u003c\/p\u003e\n\n\u003ch2 id=\"duration\"\u003eDuration, Frequency, and Types of Intervention\u003c\/h2\u003e\n\n\u003cp\u003eA total of 4,434 participants were included in the eligible randomized controlled trials. The number of participants in each trial ranged from 35 to 1,680. Intervention length ranged from 6 to 36 months.\u003c\/p\u003e\n\n\u003cp\u003eTwo randomized controlled trials had been terminated early as a consequence of the SARS-CoV-2 pandemic. These were the IRMCI and SYNERGIC trials.\u003c\/p\u003e\n\n\u003cp\u003eThe trials varied in their design:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eSeven trials had 2 arms\u003c\/li\u003e\n\u003cli\u003eTwo trials had either 3 or 4 arms\u003c\/li\u003e\n\u003cli\u003eOne trial featured 5 study arms\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eMasking, also called blinding, is a method used in clinical trials to prevent bias. The trials used different levels of masking:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eTwo studies opted for quadruple masking (participants, caregiver, investigator, and outcome assessor)\u003c\/li\u003e\n\u003cli\u003eThree studies used triple masking (participants, outcome assessor, and either investigator or caregiver)\u003c\/li\u003e\n\u003cli\u003eTwo studies used double masking (participants and outcome assessor)\u003c\/li\u003e\n\u003cli\u003eFour studies used single masking (participants or outcome assessor)\u003c\/li\u003e\n\u003cli\u003eOne trial opted for an open-label approach, meaning everyone knew which treatment was being given\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eEarlier trials incorporated 2 to 3 intervention domains. These typically combined physical exercise with either cognitive training or dietary guidance. Later studies expanded their multidomain approaches, integrating further domains such as social engagement, cardiovascular risk management, meditation, or sleep hygiene education.\u003c\/p\u003e\n\n\u003cp\u003ePhysical exercise emerged as the most frequently utilized component of intervention. It was present in all 12 randomized controlled trials. Most studies utilized moderate-to-high intensity progressive training approaches. Only 1 randomized controlled trial opted for low intensity.\u003c\/p\u003e\n\n\u003cp\u003eTen randomized controlled trials incorporated cognitive training in their intervention domains. The cognitive training varied in intensity and frequency. Dietary guidance was also included in most trials, varying between Mediterranean-like and ketogenic diets, or through general healthy dietary advice.\u003c\/p\u003e\n\n\u003cp\u003eFive randomized controlled trials incorporated guidance on social activities. These ranged from suggestions such as dancing or participating in church events to integrating social engagement within physical exercise or cognitive training domains.\u003c\/p\u003e\n\n\u003cp\u003eSix randomized controlled trials employed a combination of individual and group sessions for intervention domains. These included dietary guidance, physical exercise, and cognitive training. Personalized sessions were used to tailor the intervention, for example addressing weight loss or malnutrition. Group formats were used to foster socialization and peer support.\u003c\/p\u003e\n\n\u003cp\u003eIn contrast, 2 trials relied solely on group sessions. These excluded the individually tailored home-based exercises commonly included across studies. Three randomized controlled trials did not specify how the interventions were delivered.\u003c\/p\u003e\n\n\u003cp\u003eFour trials explicitly targeted cardiovascular or metabolic risk factor management as a distinct intervention domain. Three trials included advice on sleep hygiene, stress management, or meditation.\u003c\/p\u003e\n\n\u003cp\u003eFew randomized controlled trials, such as MET-FINGER, MAPT, and MIND-ADmini, specified that the different intervention components were gradually introduced to facilitate adherence. This information is not reported for other trials.\u003c\/p\u003e\n\n\u003cp\u003eThe transition toward targeting multiple risk factors through multidomain interventions reflects a growing emphasis on comprehensive, data-driven strategies to enhance cognitive health outcomes.\u003c\/p\u003e\n\n\u003ch2 id=\"outcomes\"\u003eHow Outcomes Were Measured\u003c\/h2\u003e\n\n\u003cp\u003eThe heterogeneity of the interventions and the varying designs across the randomized controlled trials provided limited possibility to synthesize the outcomes. The trials differed in their target groups and outcome measures. Therefore, a narrative synthesis was chosen to describe the results.\u003c\/p\u003e\n\n\u003cp\u003eOne trial was the Multimodal Preventive Trial for Alzheimer's Disease (MIND-ADmini), which was a feasibility trial. Another was the Lifestyle Intervention Program for Cognitive Impairment randomized controlled trial. In that trial, change in retinal amyloid burden was the main outcome. All other trials had changes in cognitive measures as their primary outcome.\u003c\/p\u003e\n\n\u003cp\u003eCognitive assessment tools ranged from various validated rating scales to composite scores commonly used in clinical practice. These included:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eAlzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)\u003c\/li\u003e\n\u003cli\u003eNeuropsychological Test Battery (NTB)\u003c\/li\u003e\n\u003cli\u003eClinical Dementia Rating scale (CDR)\u003c\/li\u003e\n\u003cli\u003eMontreal Cognitive Assessment (MoCA)\u003c\/li\u003e\n\u003cli\u003eMini Mental State Examination (MMSE)\u003c\/li\u003e\n\u003cli\u003eAlzheimer Disease Cooperative Study Preclinical Alzheimer Cognitive Composite (ADCS-PACC)\u003c\/li\u003e\n\u003cli\u003eRey Auditory Verbal Learning Test (RAVLT)\u003c\/li\u003e\n\u003cli\u003eStroop Color and Word Test (SCWT)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eDespite variability in these cognitive assessment tools, core domains were consistently evaluated. These domains included memory, attention, language, executive function, processing speed, and orientation. This offered a comprehensive view of cognitive function in individuals at risk for dementia.\u003c\/p\u003e\n\n\u003cp\u003eIn addition to cognitive outcomes, structural and functional neuroimaging, blood-based biomarkers, and changes in lifestyle indices were often employed as secondary outcome measures. These provided a multidimensional evaluation of intervention effects.\u003c\/p\u003e\n\n\u003ch2 id=\"omega3\"\u003eLifestyle Interventions Combined with Omega-3 Fatty Acids\u003c\/h2\u003e\n\n\u003cp\u003eOmega-3 polyunsaturated fatty acids (PUFA) have been tested in randomized controlled trials with cognitive endpoints in older individuals with or without an established dementia diagnosis. For some studies, findings pointed toward beneficial effects on cognitive symptoms.\u003c\/p\u003e\n\n\u003cp\u003eSupplementation with omega-3 polyunsaturated fatty acids was among the first combination trials conducted. This may be due to their excellent safety profile, ease of administration, and high combination potential with multiple domains of lifestyle intervention.\u003c\/p\u003e\n\n\u003cp\u003eThe Multidomain Alzheimer Preventive Trial (MAPT, clinicaltrials.gov registration number NCT00672685) was the largest 4-arm superiority combination, phase III randomized controlled trial. It included 1,680 participants, aged 70 years and older, with subjective cognitive complaints.\u003c\/p\u003e\n\n\u003cp\u003eParticipants were randomized to 1 of 4 groups:\u003c\/p\u003e\n\n\u003col\u003e\n\u003cli\u003eLifestyle intervention (physical activity advice, cognitive training, and nutritional consultations) plus omega-3 supplementation (daily dose of 800 mg DHA and 250 mg EPA)\u003c\/li\u003e\n\u003cli\u003eLifestyle intervention plus placebo\u003c\/li\u003e\n\u003cli\u003eLifestyle control (information sessions on lifestyle) plus omega-3 supplementation\u003c\/li\u003e\n\u003cli\u003eLifestyle control plus placebo\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe primary efficacy outcome was change in the composite Z score. This score was calculated from a combination of tests. The tests were the Free and Cued Selective Reminding Test, 10 MMSE orientation items, the Digit Symbol Substitution Test score from the Wechsler Adult Intelligence Scale, and the Category Naming Test.\u003c\/p\u003e\n\n\u003cp\u003eNo significant intervention effect on the primary outcome was reported. However, positive results were found in subgroup and post-hoc analyses. These positive results were particularly seen in individuals with higher dementia risk, as measured by the increased Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) dementia risk score. Positive results were also seen in participants classified as amyloid-beta-positive via brain PET scan with florbetapir. Cognitive benefits were also seen when pooling all participants who received the multidomain intervention.\u003c\/p\u003e\n\n\u003cp\u003eA smaller randomized controlled trial enrolled 45 patients with mild cognitive impairment. This was a substudy within a larger study (clinicaltrials.gov ID NCT01219244). It assessed the combined effect of lifestyle intervention (physical and cognitive domains) with omega-3 supplementation (daily dose of 880 mg DHA and 1,320 mg EPA supplemented with 15 mg vitamin E).\u003c\/p\u003e\n\n\u003cp\u003eParticipants were assessed over 6 months. Changes in composite z scores of executive function, memory, sensorimotor speed, and attention were assessed. These assessments were based on the Auditory Verbal Learning Test, forward and backward digit spans, verbal fluency, Trail Making Test part A and B, and the Stroop Color-Word Test. No significant differences were found among the study arms.\u003c\/p\u003e\n\n\u003cp\u003eHowever, this pilot study found significantly reduced atrophy (shrinkage) in frontal, parietal, and cingulate cortices following combined intervention compared with the control arm. The control arm received omega-3 fatty acid supplementation and non-aerobic exercise.\u003c\/p\u003e\n\n\u003cp\u003eNo significant changes were found in cognitive performances after a 6-month or a 36-month intervention with omega-3 fatty acids combined with multidomain lifestyle intervention. Despite this, these trials have provided important knowledge. They highlight the need to establish the right window of opportunity for such interventions, the right target populations, and the determination of the optimal dose and treatment duration.\u003c\/p\u003e\n\n\u003ch2 id=\"bbh\"\u003eLifestyle Intervention Combined with BBH-1001\u003c\/h2\u003e\n\n\u003cp\u003eBBH-1001 is a brain health supplement containing a combination of various nutrients. The specific composition includes:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eTurmeric (125 mg)\u003c\/li\u003e\n\u003cli\u003eFisetin (16.65 mg)\u003c\/li\u003e\n\u003cli\u003eGreen tea leaf extract (17.5 mg)\u003c\/li\u003e\n\u003cli\u003eEPA (75 mg)\u003c\/li\u003e\n\u003cli\u003eDHA (150 mg)\u003c\/li\u003e\n\u003cli\u003eVitamin D3 (250 IU)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis supplement was tested in combination with a multidomain lifestyle intervention. The article text provided in this source is truncated at this point, so further details about the BBH-1001 trial results are not available in the provided material.\u003c\/p\u003e\n\n\u003ch2 id=\"other\"\u003eOther Combination Approaches\u003c\/h2\u003e\n\n\u003cp\u003eThe review identified 12 combination randomized controlled trials in total. These trials combined multidomain lifestyle interventions with various pharmacological components. The pharmacological components included:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eOmega-3 fatty acids\u003c\/li\u003e\n\u003cli\u003eTramiprosate\u003c\/li\u003e\n\u003cli\u003eVitamin D\u003c\/li\u003e\n\u003cli\u003eBBH-1001\u003c\/li\u003e\n\u003cli\u003eEpigallocatechin gallate (EGCG)\u003c\/li\u003e\n\u003cli\u003eSouvenaid (a medical food)\u003c\/li\u003e\n\u003cli\u003eMetformin\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe specific results of trials testing these other compounds are not fully detailed in the provided article text. However, the overall findings suggest that well-designed interventions, tailored to the right individuals and implemented at the optimal time, may effectively improve cognition.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat These Findings Mean for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe results of this systematic review carry several important messages for patients and their families.\u003c\/p\u003e\n\n\u003cp\u003eFirst, combining multiple lifestyle changes with medications or supplements is a promising strategy for preventing cognitive decline. No single approach works for everyone, and no single risk factor tells the whole story. Addressing multiple factors at once appears more likely to help than targeting just one.\u003c\/p\u003e\n\n\u003cp\u003eSecond, timing is critical. The trials that showed the most promise tended to intervene early in the disease process, before significant cognitive decline had occurred. This means that people with risk factors for dementia, or those with subjective cognitive decline or mild cognitive impairment, may benefit most from early intervention.\u003c\/p\u003e\n\n\u003cp\u003eThird, personalization matters. The trials that found positive results often did so in specific subgroups. For example, the MAPT trial found benefits in people with higher dementia risk scores and in those with amyloid-beta plaques visible on brain scans. This suggests that precision medicine approaches, which tailor interventions to individual characteristics, may be more effective than one-size-fits-all strategies.\u003c\/p\u003e\n\n\u003cp\u003eFourth, physical exercise was the most common component across all trials. This reinforces the importance of regular physical activity as a foundation for brain health. Cognitive training and dietary guidance were also common components.\u003c\/p\u003e\n\n\u003cp\u003eFifth, the safety of omega-3 fatty acid supplementation was noted as excellent. This makes omega-3 a potentially attractive option for combination with lifestyle interventions, though the cognitive benefits in these trials were not consistently demonstrated.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of the Research\u003c\/h2\u003e\n\n\u003cp\u003eThe authors identified several limitations in the current body of research on combination trials for dementia prevention.\u003c\/p\u003e\n\n\u003cp\u003eThe heterogeneity of the interventions and the varying designs across the randomized controlled trials provided limited possibility to synthesize the outcomes. The trials differed in their target groups, intervention components, and outcome measures. This made it difficult to draw firm conclusions about which combinations work best.\u003c\/p\u003e\n\n\u003cp\u003eMany trials did not show significant effects on their primary cognitive outcomes. This does not necessarily mean the interventions were ineffective. It may mean that the right populations, the right timing, or the right outcome measures have not yet been identified.\u003c\/p\u003e\n\n\u003cp\u003eTwo trials were terminated early due to the SARS-CoV-2 pandemic. This reduced the amount of data available for analysis.\u003c\/p\u003e\n\n\u003cp\u003eSome trials did not specify how the interventions were delivered. This lack of detail makes it harder to replicate successful approaches or understand why some trials failed.\u003c\/p\u003e\n\n\u003cp\u003eThe authors note that further refinement of randomized controlled trial methodology is warranted. The methodology needs to better align with the multifaceted nature of dementia prevention and management.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations and Next Steps\u003c\/h2\u003e\n\n\u003cp\u003eBased on their findings, the authors make several recommendations for future research and clinical practice.\u003c\/p\u003e\n\n\u003cp\u003eFuture combination trials should be designed with greater attention to:\u003c\/p\u003e\n\n\u003col\u003e\n\u003cli\u003eIdentifying the right target populations, including using precision medicine approaches such as genetic screening for APOE-ε4 carriers\u003c\/li\u003e\n\u003cli\u003eDetermining the optimal window of opportunity for intervention, with early intervention appearing most promising\u003c\/li\u003e\n\u003cli\u003eEstablishing the optimal dose and treatment duration for both lifestyle and pharmacological components\u003c\/li\u003e\n\u003cli\u003eStandardizing outcome measures to allow better comparison across trials\u003c\/li\u003e\n\u003cli\u003eGradually introducing intervention components to facilitate adherence\u003c\/li\u003e\n\u003cli\u003eUsing appropriate masking (blinding) methods to reduce bias\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe authors emphasize that integrating multidomain lifestyle interventions with pharmacological treatments holds promise for advancing precision medicine approaches. These approaches aim to prevent cognitive decline and dementia by tailoring interventions to individual needs.\u003c\/p\u003e\n\n\u003cp\u003eExisting strategies for cardiovascular and cancer treatment offer useful models for testing combination therapies in Alzheimer's disease and related dementias trials. The success of combination therapy in those fields provides a roadmap for dementia prevention research.\u003c\/p\u003e\n\n\u003cp\u003eThe World-Wide FINGERS (WW-FINGERS) network, which includes 70 member countries, offers a new paradigm to prevent cognitive decline. This global collaboration allows researchers to test multidomain interventions across diverse populations and settings.\u003c\/p\u003e\n\n\u003cp\u003eFor patients and families, the key takeaway is that no single combination has yet proven definitively effective. The strategy of addressing multiple risk factors through lifestyle changes remains the most promising path forward. This strategy is combined with targeted pharmacological or nutraceutical support. Early action, personalized to individual risk profiles, appears to offer the best chance of preserving cognitive health.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eCan combining lifestyle changes with medications or supplements prevent Alzheimer's disease?\u003c\/h3\u003e\n\u003cp\u003eNo combination has yet proven definitively effective. In a review of 12 randomized trials with 4,434 participants, no single trial showed a definitive benefit on its primary cognitive outcome. Some trials found positive results in specific subgroups, particularly people at higher dementia risk. Researchers conclude that well-designed combination interventions, tailored to the right individuals at the optimal time, may effectively improve cognition.\u003c\/p\u003e\n\u003ch3\u003eWho might benefit most from these combination approaches?\u003c\/h3\u003e\n\u003cp\u003eTrials that showed promise tended to intervene early, before significant cognitive decline. Participants included people with normal cognition but increased dementia risk, subjective cognitive decline, mild cognitive impairment, or prodromal Alzheimer's disease. In the MAPT trial of 1,680 participants, positive results appeared in those with higher dementia risk scores and those with amyloid-beta plaques on brain scans, suggesting personalization matters.\u003c\/p\u003e\n\u003ch3\u003eWhat lifestyle components were tested in these combination trials?\u003c\/h3\u003e\n\u003cp\u003ePhysical exercise appeared in all 12 trials, most using moderate-to-high intensity progressive training. Ten trials included cognitive training, and most included dietary guidance, varying between Mediterranean-like and ketogenic diets or general healthy eating advice. Five trials added social activity guidance. Four targeted cardiovascular or metabolic risk management, and three included sleep hygiene, stress management, or meditation advice.\u003c\/p\u003e\n\u003ch3\u003eAre omega-3 supplements safe to combine with lifestyle changes?\u003c\/h3\u003e\n\u003cp\u003eOmega-3 polyunsaturated fatty acid supplementation was noted as having an excellent safety profile, making it a potentially attractive option for combination with lifestyle interventions. However, cognitive benefits were not consistently demonstrated. In the MAPT trial of 1,680 participants, no significant effect on the primary cognitive outcome was reported, though positive results appeared in some subgroup analyses.\u003c\/p\u003e\n\u003ch3\u003eHow long did these combination trials last, and how many people took part?\u003c\/h3\u003e\n\u003cp\u003eThe 12 randomized controlled trials enrolled a total of 4,434 participants, with individual trials ranging from 35 to 1,680 people. Intervention periods lasted from 6 to 36 months. Two trials, IRMCI and SYNERGIC, were terminated early because of the SARS-CoV-2 pandemic, which reduced the amount of data available for analysis.\u003c\/p\u003e\n\u003ch3\u003eWhat does it mean that many trials found no significant effect on their primary cognitive outcome?\u003c\/h3\u003e\n\u003cp\u003eIt does not necessarily mean the interventions were ineffective. It may mean the right populations, timing, or outcome measures have not yet been identified. The trials differed in target groups, intervention components, and outcome measures, which limited the ability to synthesize results. Researchers say trial methods need further refinement to better match the multifaceted nature of dementia prevention.\u003c\/p\u003e\n\u003ch3\u003eWhat are the next steps researchers recommend for combination trials?\u003c\/h3\u003e\n\u003cp\u003eFuture trials should identify the right target populations, including genetic screening for APOE-ε4 carriers, determine the optimal window of opportunity with early intervention appearing most promising, and establish optimal dose and treatment duration. They should also standardize outcome measures, gradually introduce intervention components to support adherence, and use appropriate masking methods to reduce bias.\u003c\/p\u003e\n\u003ch3\u003eIf I have mild cognitive impairment or a higher dementia risk score, when should I seek a second opinion about combining lifestyle changes with medications or supplements?\u003c\/h3\u003e\n\u003cp\u003eA second opinion is worth considering when you have subjective cognitive decline, mild cognitive impairment, or a higher dementia risk score, since trials such as MAPT showed cognitive benefits mainly in higher-risk subgroups and in people with amyloid-beta plaques on PET scans. Timing matters: interventions appear most promising when started early, before significant decline. Because no single combination has proven definitively effective, an independent review can clarify whether a proposed combination fits your risk profile. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Risk reduction and precision prevention across the Alzheimer's disease continuum: a systematic review of clinical trials combining multidomain lifestyle interventions and pharmacological or nutraceutical approaches.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Bereczki E, Mangialasche F, Barbera M, Padilla P, Hara Y, Fillit H, Solomon A, Kivipelto M.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e The Journal of Prevention of Alzheimer's Disease, Volume 12, 2025, Article 100367\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e https:\/\/doi.org\/10.1016\/j.tjpad.2025.100367\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eReceived:\u003c\/strong\u003e July 9, 2025; \u003cstrong\u003eRevised:\u003c\/strong\u003e September 2, 2025; \u003cstrong\u003eAccepted:\u003c\/strong\u003e September 2, 2025; \u003cstrong\u003eAvailable online:\u003c\/strong\u003e October 27, 2025\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthor affiliations:\u003c\/strong\u003e FINGERS Brain Health Institute, Karolinska Institutet, Karolinska University Hospital, University of Eastern Finland, Imperial College London, Alzheimer's Drug Discovery Foundation, Stockholms Sjukhem\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e This patient-friendly article is based on peer-reviewed research. The original article is an open-access publication distributed under the terms of the Creative Commons CC BY license.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47876009558172,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/products\/combining-lifestyle-changes-with-medications-or-supplements-to-prevent-alzheimers-disease-what-the-research-shows","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}